<DOC>
	<DOC>NCT01125475</DOC>
	<brief_summary>The primary objective is to determine adherence to RebifÂ® New Formulation administered by RebiSmart during 12 weeks of therapy in patients with RRMS.</brief_summary>
	<brief_title>A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Males and females between 18 and 65 years of age Have relapsingremitting multiple sclerosis (RRMS) according to the revised McDonald Criteria (2005) Having an expanded disability status scale (EDSS) of less than 6 at the screening visit or within 2 months prior to the screening visit Stable treatment (defined as treatment after titration period) with RebiSmart administered Rebif new formulation (RNF) 22/44 mcg subcutaneously thrice a week for a minimum of 4 weeks prior to inclusion Previously treated with disease modifying drugs (DMDs) for a minimum of 6 months prior to the screening visit Female subjects must be neither pregnant nor breastfeeding and must lack childbearing potential as defined by either: Postmenopausal or surgically sterile; or Using a highly effective method of contraception for the duration of the study. This is defined as a method that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly , and includes for instance implants, injectables, combined oral contraceptives, intrauterine device (IUD), sexual abstinence or vasectomized partner Have a scheduled visit 12 weeks after the inclusion visit Willing and able to comply with the protocol for the duration of the study Have given written informed consent Have had a relapse within 30 days prior to the first visit Have any contraindications to treatment with Interferonbeta 1a according to Summary of Product Characteristics Have any other significant disease that in the Investigator's opinion would exclude the subject from the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>RebiSmart</keyword>
	<keyword>Rebif</keyword>
	<keyword>Adherence</keyword>
</DOC>